With an onus on safety in the potential use of porcine islet cells as a treatment for diabetes, the use of animals lacking exogenous pathogens is clearly important and multilevel screening strategies have been presented on testing animals and the product. In this study, we wished to investigate whether islet cells indeed harboured the same viral pathogens of concern in the source animal. PMBC and islet cells from both adult and neonatal source animals were directly compared and tested for PCMV, PLHV, PCV2, PPV and HEV using both molecular and serological assays. Adult PBMC were found positive for all viruses with the exception of PCV2 and HEV. Neonatal PBMC were only found positive for PCMV and HEV. All animals were found negative for HEV antibodies. Interestingly, islet cells were negative for all viruses tested regardless of status in the animal-derived PBMC. Given that other laboratories have demonstrated the lack of virus detection during the culture of islets, this study also demonstrates that the hygiene status of the herd may not reflect the status of the product. This is important for establishing guidelines for any risk evaluation and mitigation process utilised during product manufacture.
| INTRODUCTION
The risk of zoonotic disease transmission to human recipients during xenotransplantation is considered one of the barriers to xenotransplantation's transition to clinical practice. 1 Such risks can be difficult to eliminate, particularly in the case of porcine endogenous retrovirus. However, this risk may be reduced by the selection of low PERVexpressing donor pigs or eliminated by the creation of PERV-free pigs via genetic manipulation. 2 The risk posed by exogenous pathogens can be minimised by thorough screening of donor animals from barrier reared herds. 3 However, it is clear that certain pathogens can be difficult to detect, particularly viruses that form latent infections, that are highly divergent or for which sensitive and specific assays are not available. 4, 5 The encapsulation of porcine islets has been evaluated as a therapeutic modality for the treatment of diabetes and, despite the lack of evidence to date of the transmission of specific exogenous viruses to both animal models and humans, evaluation of the microbiological safety of porcine islets is still required. Indeed, current methods have been evaluated. 6 It is clear that different cells, tissues and organs vary in their potential to harbour infectious pathogens, and this variation may play an important factor in assessing the risk of zoonotic infection in a particular xenotransplantation trial. 3, 6 A number of reports have characterised the pathogen status of pigs 7, 8 ; however, whether an animal's pathogen profile obtained through blood screening is reflective of the pathogen profile of its tissues or organs has not been previously investigated. It is important to note that pathogens detected in the blood may not be present in the transplanted tissue and vice versa. Given the progression of porcine islet xenotransplantation towards clinical application, 
| MATERIALS AND METHODS
Pigs (Belgian landrace) were provided by Rattlerow-Seghers Genetics (Ooigem, Belgium). Piglets were directly delivered to the islet isolation facility in Brussels. Adult pigs were housed in the A. Briefly, 50 mL heparinised blood was centrifuged at room temperature over Histopaque 1077 from Sigma (Darmstadt, Germany). The opaque interface containing PBMCs was then aspirated, washed in PBS, pelleted and stored at −70°C. Pancreatic islet isolation was carried out as detailed elsewhere. 10 Collagenase V from Sigma was used for piglet pancreas digestion, and collagenase NB8 from Serva (Heidelberg, Germany) was used for adult pancreas. We obtained 2087 ± 151 islet equivalents (IEQ)/g pancreas (purity >75%) from neonatal piglets and 234 ± 16 IEQ/g pancreas (purity >90%) from adult pigs (mean ± SEM). 17 the sensitivity of these assays was determined to be 2 copies, 10 copies, 2 copies, 10 copies, 5 copies, 5 copies and 2.5 IU per reaction, respectively. For DNA virus detection, each reaction contained 250 ng of DNA. All samples were assessed for integrity, and RNA was validated in serum and confirmed without contamination as described previously. 18 All animals had received a vaccination against mycoplasma (Stellamune, Elanco) at 14 days of age. Adult pigs had received a vaccination against porcine parvovirus and Erysipelothrix rhusiopathiae (Porcilis ERY-PARVO (Intervet International)) at 6 months of age and again after each farrowing.
| RESULTS AND DISCUSSION
As indicated, adult and neonatal animals were screened for PCMV, samples despite their presence in the PBMC or serum samples analysed. PCV-2 was not found in any of the animals tested. PCMV was only detected in the PBMC, and the remaining data are summarised in Table 1 .
As shown in Table 1 , no islet sample tested positive for any herpes virus, despite several animals testing positive in the PBMC for herpes viruses, ranging from 2.9% for PLHV2 to 38.1% for PLHV3.
In humans, cases of acute pancreatitis associated with herpes viruses such as CMV, 19 varicella zoster virus (VZV) 20 Hepatitis E has also been associated with acute pancreatitis in humans, 23 but as no islet sample tested positive for HEV, and only 1 serum sample tested positive for HEV, it is not possible to draw any conclusions regarding the potential for islet cells to harbour HEV. In addition, all animals were negative for antibodies to HEV. This study indicates that the risk of porcine islet pathogen contamination is low, regardless of age of harvest, and that, irrespective of the multilevel testing strategy, testing of the end product will be an important requirement. This report has identified an absence of correlation between the pathogen profiles of porcine PBMCs and islets,
indicating that product screening in xenotransplantation, as opposed to antemortem donor screening, provides a safer and more reliable approach. Updates to current regulations have been suggested, 6, 24 and information on the relevance of viral pathogens in specific xenotransplant products will aid to advise this.
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